Gain-of-function mutations in the PTPN11 gene, encoding SHP2, lead to Noonan syndrome, juvenile myelomonocytic leukaemia (JMML), myelodysplastic syndrome, B cell ALL, and AML. This evidence concerns the gene PTPN11 and acute myeloid leukemia.